Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

Sponsor
Xinqiao Hospital of Chongqing
Study ID
NCT03792503
Phase
PHASE4
Status
Withdrawn

Conditions

  • Advanced Non-squamous Non-small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500 mg Po qd
  • Pemetrexed — DRUG
    Pemetrexe 500 mg/m2 d1×q3w

Study Details

In order to further improve the therapeutic efficacy of advanced no-squamous non-small cell lung cancer patients, improve the life cycle, this study will take the standard after treatment pemetrexed combined other anti-angiogenesis drugs to maintain as the direction, so as to provide more over the evidence for the treatment of advanced NSCLC.

Key Dates

Start date
Feb 28, 2019
Status verified
Feb 2024
Primary completion
Feb 29, 2020
Completion
Feb 28, 2022

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib，Pemetrexe
    Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd

Primary Outcome Measure

Progression free survival（PFS） [ Time Frame: Up to three years ]

Related Studies